Plus Therapeutics Stock Fundamentals
| PSTV Stock | USD 1.26 0.02 1.56% |
Plus Therapeutics fundamentals help investors to digest information that contributes to Plus Therapeutics' financial success or failures. It also enables traders to predict the movement of Plus Stock. The fundamental analysis module provides a way to measure Plus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Plus Therapeutics stock.
At this time, Plus Therapeutics' Reconciled Depreciation is fairly stable compared to the past year. Plus | Select Account or Indicator |
Plus Therapeutics Company Return On Equity Analysis
Plus Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Plus Therapeutics Return On Equity | -5.22 |
Most of Plus Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Plus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Plus Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Plus Therapeutics has a Return On Equity of -5.225. This is 78.2% lower than that of the Biotechnology sector and 85.67% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Plus Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Plus Therapeutics's current stock value. Our valuation model uses many indicators to compare Plus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Plus Therapeutics competition to find correlations between indicators driving Plus Therapeutics's intrinsic value. More Info.Plus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Plus Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Plus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Plus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Plus Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Plus Therapeutics could also be used in its relative valuation, which is a method of valuing Plus Therapeutics by comparing valuation metrics of similar companies.Plus Therapeutics is currently under evaluation in return on equity category among its peers.
Plus Fundamentals
| Return On Equity | -5.22 | ||||
| Return On Asset | -0.69 | ||||
| Profit Margin | (2.40) % | ||||
| Operating Margin | (2.89) % | ||||
| Current Valuation | 6.04 M | ||||
| Shares Outstanding | 5.9 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 11.30 % | ||||
| Number Of Shares Shorted | 103.98 K | ||||
| Price To Book | 3.76 X | ||||
| Price To Sales | 1.35 X | ||||
| Revenue | 4.91 M | ||||
| Gross Profit | (9.47 M) | ||||
| EBITDA | (12.69 M) | ||||
| Net Income | (13.32 M) | ||||
| Cash And Equivalents | 20.27 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 4.18 M | ||||
| Debt To Equity | 0.53 % | ||||
| Current Ratio | 2.81 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (12.85 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | (2.33) X | ||||
| Target Price | 16.0 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 7.43 M | ||||
| Total Asset | 11.39 M | ||||
| Retained Earnings | (480.5 M) | ||||
| Working Capital | (893 K) | ||||
| Net Asset | 11.39 M |
About Plus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Plus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.3 M | 1.2 M | |
| Total Revenue | 4.9 M | 5.6 M | |
| Cost Of Revenue | 9.7 M | 10.2 M | |
| Stock Based Compensation To Revenue | 0.12 | 0.11 | |
| Sales General And Administrative To Revenue | 1.74 | 3.24 | |
| Research And Ddevelopement To Revenue | 1.97 | 2.99 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 1.56 | 1.49 | |
| Ebit Per Revenue | (3.12) | (3.27) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.